CTOs on the Move

Progenity

www.progenity.com

 
Progenity, Inc. is a biotechnology company innovating in the fields of women`s health, gastrointestinal health, and oral biotherapeutics. Progenity applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity`s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.progenity.com
  • 4330 La Jolla Village Drive
    San Diego, CA USA 92122
  • Phone: 855.293.2639

Executives

Name Title Contact Details
Paul Shabram
Senior Vice President of Technical Operations Profile
Launa Saunders
Director of IT, Sales and Marketing Platforms Profile
Troy Seelye
Senior Vice President and Chief Information Officer Profile

Funding

Progenity raised $125M on 11/07/2017
Progenity raised $40M on 06/10/2021

Similar Companies

Genome Atlantic

Genome Atlantic is a Halifax, NS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Patara Pharma

Patara Pharma is a biopharmaceutical company developing a new therapy for the treatment of allergic and immunologic diseases and conditions that affect orphan patient populations. We completed a Phase 1 clinical trial with favorable results and have initiated Phase 2 clinical trials for several undisclosed indications that will read-out by the end of 2015.

Tissue Gnostics

Tissue Gnostics is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immunomic Therapuetics

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company headquartered in Hershey, PA with lab facilities in Rockville, MD. ITI is developing next generation vaccines based on the patented Lysosomal Associated Membrane Protein, or LAMP, Technology. Our LAMP-Vax™ vaccine platform significantly increases the effectiveness of the immune response to nucleic acid vaccines while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies. LAMP emerged from $20 million of NIH-funded research conducted by distinguished scientist Dr. Tom August at the Johns Hopkins University School of Medicine. ITI has the exclusive worldwide license to the LAMP technology patent estate and is commercializing ground-breaking next generation LAMP DNA vaccines, beginning with allergy, cancer and infectious disease.

Vysis

Vysis, Inc. is a Downers Grove, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.